Table 1.
Characteristics of the 129 MDR/XDR P. aeruginosa isolates.
| Characteristics | n (%) |
|---|---|
| Type of sample | |
| Respiratory | 59 (45.8) |
| Urine | 51 (39.5) |
| Surgical wound | 9 (7.0) |
| Blood | 2 (1.6%) |
| Catheter | 1 (0.8%) |
| Others | 7 (5.4) |
| Origin of patient | |
| In-patient | 99 (76.8%) |
| Out-patient | 30 (23.2) |
| MDR | 12 (9.3) |
| XDR | 117 (90.7) |
| Isolates susceptible to: | |
| Amikacin | 101 (78.2) |
| Gentamicin | 31 (24.0) |
| Tobramycin | 54 (41.9) |
| Ceftazidime | 13 (10.1) |
| Cefepime | 14 (10.8) |
| Piperacillin-tazobactam | 8 (6.2) |
| Ceftolozane-tazobactam | 119 (92.2) |
| Imipenem | 16 (12.4) |
| Meropenem | 7 (5.4) |
| Aztreonam | 0 (0) |
| Ciprofloxacin | 10 (7.0) |
| Levofloxacin | 5 (3.9) |
| Colistin | 128 (99.2) |
| Isolates only susceptible to colistin and amikacin | 49 (38) |
| Isolates only susceptible to colistin | 13 (10.1) |